Daina Avizonis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daina Avizonis has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Mariana De Sa Tavares Russo
McGill University 3 Rosalind & Morris Goodman Cancer Institute Montréal, Québec, Canada
3 shared publications - Aaron DiAntonio
Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO 63110, USA
1 shared publication Alain Pacis
Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, Canada
1 shared publication- Alyssa M. Weinrauch
Life Sciences Institute, Department of Cellular and Physiological Sciences & Department of Surgery University of British Columbia Vancouver British Columbia Canada
1 shared publication Andrew Craig
1 shared publication- Anie Monast
McGill University 3 Rosalind & Morris Goodman Cancer Institute Montréal, Québec, Canada
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by Wiley in Protein Science
- Vol. 35 (12)
ProteoAnalyst : Connecting biological context and peptide‐level evidence in quantitative proteomics and phosphoproteomics
Modern mass spectrometry now routinely quantifies thousands of proteins and phosphosites. While raw spectral processing and quantification have matured over the past few years, downstream statistical analysis and functional interpretation remain challenging. Current tools are often fragmented across separate applications for statistics, enrichment, network analysis, and phosphoproteomics. Furthermore, they operate largely at the protein or site level, leaving the supporting peptide, precursor, and phosphosite measurements out of reach; while pathway and network visualizations are provided without subcellular context. To address these limitations, we developed ProteoAnalyst, an easy‐to‐use web‐based platform that takes common upstream outputs (MaxQuant, FragPipe, DIA‐NN, and Spectronaut) through quality control, statistical analysis, and functional interpretation within a single environment. Researchers can navigate from pathways, compartment‐aware interaction networks, and kinase‐substrate networks down to the individual proteins, peptides, precursors, and phosphosites that support them. Dedicated modules extend this capacity to peptide‐level detection of isoform usage and post‐translational modification (PTM) relative fractions, phosphoproteomics with protein abundance correction, and biomarker analysis. Our benchmarks and case studies demonstrate that ProteoAnalyst integrates well‐established methods with rich functional analysis and visualization to streamline data interpretation and hypothesis generation. ProteoAnalyst is freely available at www.proteoanalyst.ca .
- 12 November 2026
- Published by Wiley in Protein Science
- Vol. 35 (12)
Open AccessProteoAnalyst : Connecting biological context and peptide‐level evidence in quantitative proteomics and phosphoproteomics
Modern mass spectrometry now routinely quantifies thousands of proteins and phosphosites. While raw spectral processing and quantification have matured over the past few years, downstream statistical analysis and functional interpretation remain challenging. Current tools are often fragmented across separate applications for statistics, enrichment, network analysis, and phosphoproteomics. Furthermore, they operate largely at the protein or site level, leaving the supporting peptide, precursor, and phosphosite measurements out of reach; while pathway and network visualizations are provided without subcellular context. To address these limitations, we developed ProteoAnalyst, an easy‐to‐use web‐based platform that takes common upstream outputs (MaxQuant, FragPipe, DIA‐NN, and Spectronaut) through quality control, statistical analysis, and functional interpretation within a single environment. Researchers can navigate from pathways, compartment‐aware interaction networks, and kinase‐substrate networks down to the individual proteins, peptides, precursors, and phosphosites that support them. Dedicated modules extend this capacity to peptide‐level detection of isoform usage and post‐translational modification (PTM) relative fractions, phosphoproteomics with protein abundance correction, and biomarker analysis. Our benchmarks and case studies demonstrate that ProteoAnalyst integrates well‐established methods with rich functional analysis and visualization to streamline data interpretation and hypothesis generation. ProteoAnalyst is freely available at www.proteoanalyst.ca .
- 28 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF17
EZH2 Inhibition Induces a Metabolic Stress Response, Sensitizing Triple-Negative Breast Cancer to Glutaminase Targeting
Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the histone methyltransferase complex polycomb repressive complex 2, is overexpressed and associated with a poor prognosis in triple-negative breast cancer (TNBC). Although EZH2 inhibition significantly alters chromatin landscapes and gene expression, it has a limited impact on the growth of TNBC models, suggesting adaptive compensatory mechanisms. In this study, we demonstrated that EZH2 inhibition causes the accumulation of misfolded proteins and double-stranded RNA, triggering an essential integrated stress response (ISR) through protein kinase R and protein kinase RNA–like endoplasmic reticulum kinase activation. By inducing ISR-mediated activating transcription factor 4 (ATF4), EZH2 inhibition enhanced amino acid flux and promoted glutaminolysis to support TNBC cell survival. Pharmacologic targeting of this metabolic axis with a glutaminase inhibitor in combination with EZH2 inhibition significantly impaired TNBC cell proliferation and tumor growth. These findings reveal a stress-driven metabolic adaptation that sustains TNBC survival upon EZH2 blockade and highlight the inhibition of this pathway as a strategy to enhance the efficacy of EZH2 inhibitors in TNBC. Significance: By inducing integrated stress response–ATF4-mediated metabolic rewiring, EZH2 inhibition creates a critical glutamine dependency in triple-negative breast cancer, exposing an actionable vulnerability through co-inhibition of glutaminase.
- 28 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF17
EZH2 Inhibition Induces a Metabolic Stress Response, Sensitizing Triple-Negative Breast Cancer to Glutaminase Targeting
Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the histone methyltransferase complex polycomb repressive complex 2, is overexpressed and associated with a poor prognosis in triple-negative breast cancer (TNBC). Although EZH2 inhibition significantly alters chromatin landscapes and gene expression, it has a limited impact on the growth of TNBC models, suggesting adaptive compensatory mechanisms. In this study, we demonstrated that EZH2 inhibition causes the accumulation of misfolded proteins and double-stranded RNA, triggering an essential integrated stress response (ISR) through protein kinase R and protein kinase RNA–like endoplasmic reticulum kinase activation. By inducing ISR-mediated activating transcription factor 4 (ATF4), EZH2 inhibition enhanced amino acid flux and promoted glutaminolysis to support TNBC cell survival. Pharmacologic targeting of this metabolic axis with a glutaminase inhibitor in combination with EZH2 inhibition significantly impaired TNBC cell proliferation and tumor growth. These findings reveal a stress-driven metabolic adaptation that sustains TNBC survival upon EZH2 blockade and highlight the inhibition of this pathway as a strategy to enhance the efficacy of EZH2 inhibitors in TNBC. Significance: By inducing integrated stress response–ATF4-mediated metabolic rewiring, EZH2 inhibition creates a critical glutamine dependency in triple-negative breast cancer, exposing an actionable vulnerability through co-inhibition of glutaminase.
- Open Access
- 31 August 2026
- Published by Elsevier in SSRN Electronic Journal
Mitochondrial Cristae Integrity as a Stress-Sensing Hub that Engages ATF4-Dependent Adaptive Programs
How cells sense disruption of mitochondrial architecture and couple it to adaptive metabolic stress responses remains poorly understood. Here, we investigated the consequences of perturbing mitochondrial fusion and fission in breast cancer cells and found that loss of the inner membrane fusion protein Opa1, but not the fission regulator Drp1, elicited profound metabolic and transcriptional remodeling. Opa1 silencing disrupted cristae architecture, impaired mitochondrial respiration and induced an ATF4-dependent reprogramming of amino acid metabolism pathways. Mechanistically, ATF4 induction was heightened upon removal of extracellular pyruvate, phenocopied by pharmacological inhibition of electron transport chain (ETC) complex I and required the amino acid-dependent stress kinase GCN2. In contrast, inhibition of ATP synthase (complex V) activated distinct signaling mechanisms that were independent of pyruvate availability or aspartate supplementation, indicating that individual respiratory defects engage mechanistically distinct stress responsive pathways. Functionally, complex I-dependent mitochondrial stress attenuated DNA damage caused by chemotherapeutic agents that target one-carbon metabolism. Together, our findings identify mitochondrial cristae integrity as a critical regulator linking ETC dysfunction to a GCN2-dependent ISR, thereby reshaping metabolic adaptation and therapeutic responsiveness in cancer cells.
- 31 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMitochondrial Cristae Integrity as a Stress-Sensing Hub that Engages ATF4-Dependent Adaptive Programs
How cells sense disruption of mitochondrial architecture and couple it to adaptive metabolic stress responses remains poorly understood. Here, we investigated the consequences of perturbing mitochondrial fusion and fission in breast cancer cells and found that loss of the inner membrane fusion protein Opa1, but not the fission regulator Drp1, elicited profound metabolic and transcriptional remodeling. Opa1 silencing disrupted cristae architecture, impaired mitochondrial respiration and induced an ATF4-dependent reprogramming of amino acid metabolism pathways. Mechanistically, ATF4 induction was heightened upon removal of extracellular pyruvate, phenocopied by pharmacological inhibition of electron transport chain (ETC) complex I and required the amino acid-dependent stress kinase GCN2. In contrast, inhibition of ATP synthase (complex V) activated distinct signaling mechanisms that were independent of pyruvate availability or aspartate supplementation, indicating that individual respiratory defects engage mechanistically distinct stress responsive pathways. Functionally, complex I-dependent mitochondrial stress attenuated DNA damage caused by chemotherapeutic agents that target one-carbon metabolism. Together, our findings identify mitochondrial cristae integrity as a critical regulator linking ETC dysfunction to a GCN2-dependent ISR, thereby reshaping metabolic adaptation and therapeutic responsiveness in cancer cells.
- Open Access
- 1 July 2026
- Published by Wiley in JCSM Communications
- Vol. 9 (2)
D 3 ‐Creatine Derived Skeletal Muscle Mass Correlates With Grip Strength in (Pre)frail Older Adult Patients Undergoing Cardiac Surgery
Background: (Pre)frail older adult patients undergoing cardiac surgery experience disproportionate mortality and prolonged length of stay, underpinned by low skeletal muscle mass (SMM), which is central to the underlying frailty pathophysiology. Conventional methods for assessing SMM have well‐recognized limitations in this population. The D 3 ‐creatine (D 3 ‐Cr) dilution method offers a non‐invasive, direct estimate of total‐body SMM. Pre‐surgery D 3 ‐Cr derived SMM and its relationship with strength, physical performance and multidimensional health status measures in (pre)frail older adult patients undergoing cardiac surgery have not been explored. Methods: Seventeen (pre)frail older adult patients (16 male, 1 female; median 75 [interquartile range: 67–75] years; body mass index 28.7 [24.2–29.9] kg/m 2 ; Clinical Frailty Scale 3 [3, 4]) ingested a single 30‐mg oral dose of D 3 ‐Cr 3.5 [3.0–4.3] days prior to scheduled elective or non‐emergent (inpatient) cardiac surgery. Spot urine was collected pre‐dose and 48–72 h post‐dose, and D 3 ‐creatinine (D 3 ‐Crn) and unlabelled creatine and creatinine were quantified by liquid chromatography–tandem mass spectrometry. Total‐body SMM was estimated using a published spillage‐correction algorithm; both a height‐adjusted and body weight–adjusted SMM index were calculated as SMM divided by height squared and SMM divided by body weight. Spearman's rank correlations (r s ) between strength, physical performance outcomes and multidimensional health status measures and (i) absolute SMM, (ii) height‐adjusted SMM index and (iii) body weight–adjusted SMM index were calculated; bias‐corrected and accelerated bootstrap (10 000 resamples) provided 95% confidence intervals (CIs). Kendall's τ was also calculated as a sensitivity analysis. Results: Median absolute total‐body SMM derived from D 3 ‐Cr dilution was 31.7 [27.4–40.9] kg, and the corresponding height‐adjusted and body weight–adjusted SMM index was 10.8 [9.7–13.7] and 41.7 [36.1–47.4]. Handgrip strength positively associated with absolute SMM, r s = 0.61 (95% CI [0.12, 0.91], n = 14, p = 0.02) and height‐adjusted SMM index, r s = 0.55 (95% CI [0.03, 0.88], n = 14, p = 0.04), but not body weight–adjusted SMM index. The 5× sit‐to‐stand, 4‐m gait speed, balance, Short Physical Performance Battery score, length of stay, SF‐36 physical functioning score and Mini Nutritional Assessment score were not significantly associated with absolute, height‐adjusted or body weight–adjusted SMM (all p ≥ 0.10). Conclusions: The D 3 ‐Cr dilution method can be applied for the pre‐operative assessment of SMM in (pre)frail older cardiac surgery patients. Handgrip strength tracked with both absolute and height‐adjusted D 3 ‐Cr derived SMM, providing preliminary support for an association between D 3 ‐Cr derived muscle mass and grip strength in older cardiac surgery patients.
- 1 July 2026
- Published by Wiley in JCSM Communications
- Vol. 9 (2)
Open AccessD 3 ‐Creatine Derived Skeletal Muscle Mass Correlates With Grip Strength in (Pre)frail Older Adult Patients Undergoing Cardiac Surgery
Background: (Pre)frail older adult patients undergoing cardiac surgery experience disproportionate mortality and prolonged length of stay, underpinned by low skeletal muscle mass (SMM), which is central to the underlying frailty pathophysiology. Conventional methods for assessing SMM have well‐recognized limitations in this population. The D 3 ‐creatine (D 3 ‐Cr) dilution method offers a non‐invasive, direct estimate of total‐body SMM. Pre‐surgery D 3 ‐Cr derived SMM and its relationship with strength, physical performance and multidimensional health status measures in (pre)frail older adult patients undergoing cardiac surgery have not been explored. Methods: Seventeen (pre)frail older adult patients (16 male, 1 female; median 75 [interquartile range: 67–75] years; body mass index 28.7 [24.2–29.9] kg/m 2 ; Clinical Frailty Scale 3 [3, 4]) ingested a single 30‐mg oral dose of D 3 ‐Cr 3.5 [3.0–4.3] days prior to scheduled elective or non‐emergent (inpatient) cardiac surgery. Spot urine was collected pre‐dose and 48–72 h post‐dose, and D 3 ‐creatinine (D 3 ‐Crn) and unlabelled creatine and creatinine were quantified by liquid chromatography–tandem mass spectrometry. Total‐body SMM was estimated using a published spillage‐correction algorithm; both a height‐adjusted and body weight–adjusted SMM index were calculated as SMM divided by height squared and SMM divided by body weight. Spearman's rank correlations (r s ) between strength, physical performance outcomes and multidimensional health status measures and (i) absolute SMM, (ii) height‐adjusted SMM index and (iii) body weight–adjusted SMM index were calculated; bias‐corrected and accelerated bootstrap (10 000 resamples) provided 95% confidence intervals (CIs). Kendall's τ was also calculated as a sensitivity analysis. Results: Median absolute total‐body SMM derived from D 3 ‐Cr dilution was 31.7 [27.4–40.9] kg, and the corresponding height‐adjusted and body weight–adjusted SMM index was 10.8 [9.7–13.7] and 41.7 [36.1–47.4]. Handgrip strength positively associated with absolute SMM, r s = 0.61 (95% CI [0.12, 0.91], n = 14, p = 0.02) and height‐adjusted SMM index, r s = 0.55 (95% CI [0.03, 0.88], n = 14, p = 0.04), but not body weight–adjusted SMM index. The 5× sit‐to‐stand, 4‐m gait speed, balance, Short Physical Performance Battery score, length of stay, SF‐36 physical functioning score and Mini Nutritional Assessment score were not significantly associated with absolute, height‐adjusted or body weight–adjusted SMM (all p ≥ 0.10). Conclusions: The D 3 ‐Cr dilution method can be applied for the pre‐operative assessment of SMM in (pre)frail older cardiac surgery patients. Handgrip strength tracked with both absolute and height‐adjusted D 3 ‐Cr derived SMM, providing preliminary support for an association between D 3 ‐Cr derived muscle mass and grip strength in older cardiac surgery patients.
- Open Access
- 3 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Targeting fatty acid oxidation enhances response to HER2-targeted therapy
Metabolic reprogramming, a hallmark of tumorigenesis, involves alterations in glucose and fatty acid metabolism. Here, we investigate the role of Carnitine palmitoyl transferase 1a (Cpt1a), a key enzyme in long-chain fatty acid (LCFA) oxidation, in ErbB2-driven breast cancers. In ErbB2+ breast cancer models, ablation of Cpt1a delays tumor onset, growth, and metastasis. However, Cpt1a-deficient cells exhibit increased glucose dependency that enables survival and eventual tumor progression. Consequently, these cells exhibit heightened oxidative stress and upregulated nuclear factor erythroid 2-related factor 2 (Nrf2) activity. Inhibiting Nrf2 or silencing its expression reduces proliferation and glucose consumption in Cpt1a-deficient cells. Combining the ketogenic diet, composed of LCFAs, or an anti-ErbB2 monoclonal antibody (mAb) with Cpt1a deficiency significantly perturbs tumor growth, enhances apoptosis, and reduces lung metastasis. Using an immunocompetent model, we show that Cpt1a inhibition promotes an antitumor immune microenvironment, thereby enhancing the efficacy of anti-ErbB2 mAbs. Our findings underscore the importance of targeting fatty acid oxidation alongside HER2-targeted therapies to combat resistance in HER2+ breast cancer patients.
- 3 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Open AccessTargeting fatty acid oxidation enhances response to HER2-targeted therapy
Metabolic reprogramming, a hallmark of tumorigenesis, involves alterations in glucose and fatty acid metabolism. Here, we investigate the role of Carnitine palmitoyl transferase 1a (Cpt1a), a key enzyme in long-chain fatty acid (LCFA) oxidation, in ErbB2-driven breast cancers. In ErbB2+ breast cancer models, ablation of Cpt1a delays tumor onset, growth, and metastasis. However, Cpt1a-deficient cells exhibit increased glucose dependency that enables survival and eventual tumor progression. Consequently, these cells exhibit heightened oxidative stress and upregulated nuclear factor erythroid 2-related factor 2 (Nrf2) activity. Inhibiting Nrf2 or silencing its expression reduces proliferation and glucose consumption in Cpt1a-deficient cells. Combining the ketogenic diet, composed of LCFAs, or an anti-ErbB2 monoclonal antibody (mAb) with Cpt1a deficiency significantly perturbs tumor growth, enhances apoptosis, and reduces lung metastasis. Using an immunocompetent model, we show that Cpt1a inhibition promotes an antitumor immune microenvironment, thereby enhancing the efficacy of anti-ErbB2 mAbs. Our findings underscore the importance of targeting fatty acid oxidation alongside HER2-targeted therapies to combat resistance in HER2+ breast cancer patients.
- Open Access
- 22 December 2021
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 221 (2)
Sarm1 activation produces cADPR to increase intra-axonal Ca++ and promote axon degeneration in PIPN
Cancer patients frequently develop chemotherapy-induced peripheral neuropathy (CIPN), a painful and long-lasting disorder with profound somatosensory deficits. There are no effective therapies to prevent or treat this disorder. Pathologically, CIPN is characterized by a “dying-back” axonopathy that begins at intra-epidermal nerve terminals of sensory neurons and progresses in a retrograde fashion. Calcium dysregulation constitutes a critical event in CIPN, but it is not known how chemotherapies such as paclitaxel alter intra-axonal calcium and cause degeneration. Here, we demonstrate that paclitaxel triggers Sarm1-dependent cADPR production in distal axons, promoting intra-axonal calcium flux from both intracellular and extracellular calcium stores. Genetic or pharmacologic antagonists of cADPR signaling prevent paclitaxel-induced axon degeneration and allodynia symptoms, without mitigating the anti-neoplastic efficacy of paclitaxel. Our data demonstrate that cADPR is a calcium-modulating factor that promotes paclitaxel-induced axon degeneration and suggest that targeting cADPR signaling provides a potential therapeutic approach for treating paclitaxel-induced peripheral neuropathy (PIPN).
- 22 December 2021
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 221 (2)
Open AccessSarm1 activation produces cADPR to increase intra-axonal Ca++ and promote axon degeneration in PIPN
Cancer patients frequently develop chemotherapy-induced peripheral neuropathy (CIPN), a painful and long-lasting disorder with profound somatosensory deficits. There are no effective therapies to prevent or treat this disorder. Pathologically, CIPN is characterized by a “dying-back” axonopathy that begins at intra-epidermal nerve terminals of sensory neurons and progresses in a retrograde fashion. Calcium dysregulation constitutes a critical event in CIPN, but it is not known how chemotherapies such as paclitaxel alter intra-axonal calcium and cause degeneration. Here, we demonstrate that paclitaxel triggers Sarm1-dependent cADPR production in distal axons, promoting intra-axonal calcium flux from both intracellular and extracellular calcium stores. Genetic or pharmacologic antagonists of cADPR signaling prevent paclitaxel-induced axon degeneration and allodynia symptoms, without mitigating the anti-neoplastic efficacy of paclitaxel. Our data demonstrate that cADPR is a calcium-modulating factor that promotes paclitaxel-induced axon degeneration and suggest that targeting cADPR signaling provides a potential therapeutic approach for treating paclitaxel-induced peripheral neuropathy (PIPN).
- Open Access
- 6 October 2021
- Published by Taylor & Francis in Autophagy
- Vol. 18 (6) , 1256-1273
Autophagy-dependent glutaminolysis drives superior IL21 production in HIV-1-specific CD4 T cells
The maintenance of a strong IL21 production in memory CD4 T cells, especially in HIV-1-specific cells, represents a major correlate of natural immune protection against the virus. However, the molecular mechanisms underlying IL21 production during HIV-1 infection, which is only elevated among the naturally protected elite controllers (EC), are still unknown. We recently found out that lipophagy is a critical immune mediator that control an antiviral metabolic state following CD8A T cell receptor engagement, playing an important role in the natural control of HIV-1 infection. This led us to investigate whether the beneficial role of a strong macroautophagy/autophagy, could also be used to ensure effective IL21 production as well. Herein, we confirm that after both polyclonal and HIV-1-specific activation, memory CD4 T cells (Mem) from EC display enhanced activity of the autophagy-mediated proteolysis compared to ART. Our results indicate that the enhanced autophagy activity in EC was controlled by the energy-sensing PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1). We further confirmed the critical role of the autophagy-mediated proteolysis in the strong IL21 production in EC by using BECN1 gene silencing as well as protease, PRKAA1, and lysosomal inhibitors. Finally, we established that high autophagy-mediated proteolysis in EC fuels their cellular rates of mitochondrial respiration due to glutaminolysis. Our data confirm the critical role of autophagy in dictating the metabolic input, which is required not only to ensure protective cytotoxic CD8A T cell responses, but also to provide strong IL21 production among antiviral CD4 T cells. Abbreviations: AKG: alpha-ketoglutarate; ART: patients under antiretroviral therapy; ATG7: autophagy related 7; BaF: bafilomycin A1; BECN1: beclin 1; Chloro.: chloroquine; EC: elite controllers; EIF4EBP1: eukaryotic translation initiation factor 4E binding protein 1; FOXO3: forkhead box O3; GLS: glutaminase; GLUD1: glutamate dehydrogenase 1; HIVneg: HIV-1-uninfected control donors; IFNG/IFN-γ: interferon gamma; IL21: interleukin 21; MTOR: mechanistic target of rapamycin kinase; PBMC: peripheral blood mononuclear cells; PRKAA1: protein kinase AMP-activated catalytic subunit alpha 1; SQSTM1: sequestosome 1; TCA: tricarboxylic acid cycle; ULK1: unc-51 like autophagy activating kinase
- 6 October 2021
- Published by Taylor & Francis in Autophagy
- Vol. 18 (6) , 1256-1273
Open AccessAutophagy-dependent glutaminolysis drives superior IL21 production in HIV-1-specific CD4 T cells
The maintenance of a strong IL21 production in memory CD4 T cells, especially in HIV-1-specific cells, represents a major correlate of natural immune protection against the virus. However, the molecular mechanisms underlying IL21 production during HIV-1 infection, which is only elevated among the naturally protected elite controllers (EC), are still unknown. We recently found out that lipophagy is a critical immune mediator that control an antiviral metabolic state following CD8A T cell receptor engagement, playing an important role in the natural control of HIV-1 infection. This led us to investigate whether the beneficial role of a strong macroautophagy/autophagy, could also be used to ensure effective IL21 production as well. Herein, we confirm that after both polyclonal and HIV-1-specific activation, memory CD4 T cells (Mem) from EC display enhanced activity of the autophagy-mediated proteolysis compared to ART. Our results indicate that the enhanced autophagy activity in EC was controlled by the energy-sensing PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1). We further confirmed the critical role of the autophagy-mediated proteolysis in the strong IL21 production in EC by using BECN1 gene silencing as well as protease, PRKAA1, and lysosomal inhibitors. Finally, we established that high autophagy-mediated proteolysis in EC fuels their cellular rates of mitochondrial respiration due to glutaminolysis. Our data confirm the critical role of autophagy in dictating the metabolic input, which is required not only to ensure protective cytotoxic CD8A T cell responses, but also to provide strong IL21 production among antiviral CD4 T cells. Abbreviations: AKG: alpha-ketoglutarate; ART: patients under antiretroviral therapy; ATG7: autophagy related 7; BaF: bafilomycin A1; BECN1: beclin 1; Chloro.: chloroquine; EC: elite controllers; EIF4EBP1: eukaryotic translation initiation factor 4E binding protein 1; FOXO3: forkhead box O3; GLS: glutaminase; GLUD1: glutamate dehydrogenase 1; HIVneg: HIV-1-uninfected control donors; IFNG/IFN-γ: interferon gamma; IL21: interleukin 21; MTOR: mechanistic target of rapamycin kinase; PBMC: peripheral blood mononuclear cells; PRKAA1: protein kinase AMP-activated catalytic subunit alpha 1; SQSTM1: sequestosome 1; TCA: tricarboxylic acid cycle; ULK1: unc-51 like autophagy activating kinase